Old Web
English
Sign In
Acemap
>
authorDetail
>
Magdalena Pirozek-Lawniczek
Magdalena Pirozek-Lawniczek
Actelion
Medicine
Ponesimod
Teriflunomide
in patient
orally active
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
2021
JAMA Neurology
Ludwig Kappos
Robert J. Fox
Michel Burcklen
Mark S. Freedman
Eva Havrdova
Brian Hennessy
Reinhard Hohlfeld
Fred D. Lublin
Xavier Montalban
Carlo Pozzilli
Tatiana Scherz
Daniele DAmbrosio
Philippe Linscheid
Andrea Vaclavkova
Magdalena Pirozek-Lawniczek
Hilke Kracker
Till Sprenger
Show All
Source
Cite
Save
Citations (12)
Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (1770)
2020
Neurology
Till Sprenger
Michel Burcklen
Mark S. Freedman
Robert J. Fox
Eva Havrdova
Brian Hennessy
Reinhard Hohlfeld
Fred D. Lublin
Xavier Montalban
Carlo Pozzilli
Andrea Vaclavkova
Tatiana Scherz
Philippe Linscheid
Magdalena Pirozek-Lawniczek
Hilke Kracker
Ludwig Kappos
Show All
Source
Cite
Save
Citations (0)
Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972)
2020
Neurology
Robert J. Fox
Ludwig Kappos
Michel Burcklen
Mark S. Freedman
Eva Havrdova
Brian Hennessy
Reinhard Hohlfeld
Fred D. Lublin
Xavier Montalban
Carlo Pozzilli
Tatiana Scherz
Philippe Linscheid
Magdalena Pirozek-Lawniczek
Hilke Kracker
Till Sprenger
Show All
Source
Cite
Save
Citations (3)
1
map